Literature DB >> 7101905

Hodgkin's disease in a community oncology center: ten years' experience.

T M Beck, P Montgomery, C E Smith.   

Abstract

A total of 77 cases of Hodgkin's disease have been evaluated and the patients treated at our institution during the past ten years. Advances in diagnostic technology and therapy have improved the outcome of the disease and overall survival. Therapy during this period has not been standardized. Radiation therapy was the primary initial treatment for stages I, II and III, with combined-modality therapy or chemotherapy alone used for more advanced stages. Five-year disease-free and overall survival for stage IA is 81 percent and 95 percent, respectively; 74 percent and 78 percent for stage IIA; 70 percent in both instances for stage IIB; 54 percent and 100 percent for stage IIIA; 75 percent and 100 percent for stage IIIB, and 57 percent and 69 percent for stage IV. Of 13 patients initially treated with chemotherapy, 77 percent have had a complete response. Of the 16 patients (88 percent) having a relapse, 14 have been salvaged with a variety of therapeutic approaches. Overall, five-year survival for 77 patients is 86 percent, with 70 percent having no relapse.

Entities:  

Mesh:

Year:  1982        PMID: 7101905      PMCID: PMC1273788     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  12 in total

1.  Combined modality therapy of Hodgkin's disease: a report on the Stanford Trials.

Authors:  S A Rosenberg; H S Kaplan; C S Portlock; E J Glatstein
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

2.  Initial relapses in previously treated Hodgkin's disease. I. Results of second treatment.

Authors:  S A Weller; E Glatstein; H S Kaplan; S A Rosenberg
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

Review 3.  The staging and treatment of Hodgkin's disease.

Authors:  A C Aisenberg
Journal:  N Engl J Med       Date:  1978-11-30       Impact factor: 91.245

Review 4.  The chemotherapy of Hodgkin's disease: past experiences and future directions.

Authors:  V T DeVita; B J Lewis; M Rozencweig; F M Muggia
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

5.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

6.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

7.  Stages IIB and IIIB Hodgkin's disease. Results of combined modality treatment.

Authors:  R Goodman; P Mauch; A Piro; D Rosenthal; M Goldstein; J Tullis; S Hellman
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

8.  The place of radiation therapy in the treatment of Hodgkin's disease.

Authors:  S Hellman; P Mauch; R L Goodman; D S Rosenthal; W C Moloney
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

9.  Improved survival in hodgkin's disease.

Authors:  A C Aisenberg; R Qazi
Journal:  Cancer       Date:  1976-05       Impact factor: 6.860

10.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.